Biotechnology - Publications - Faculty & Research - Harvard Business School

Filter Results: (449)

Filter Results: (449)

Show Results For

← Page 12 of 449 Results →

Sort by

Are you looking for?

→Search All HBS Web

November 2020
Supplement

Valuing Celgene's CVR

By: Benjamin C. Esty and Daniel Fisher

When Bristol-Myers Squibb (BMS) acquired Celgene Corporation in November 2019, Celgene shareholders received cash, BMS stock, and a contingent value right (CVRs) that would pay $9 if the U.S. Food and Drug Administration (FDA) approved three of Celgene’s late stage... View Details

Keywords: Mergers and Acquisitions; Value; Valuation; Judgments; Decision Making; Cash Flow; Financial Instruments; Cognition and Thinking; Biotechnology Industry; Biotechnology Industry; United States

October 2019 (Revised April 2020)
Background Note

Note on Funding Deep Tech Startups

By: Karim Lakhani, Peter Barrett and Noubar Afeyan

This Background Note provides essential information on funding deep technologies—those technologies that were inherently capital intensive, time consuming, risky, and potentially disruptive. Both dilutive and non-dilutive sources of investment are highlighted, along... View Details

September 2019
Case

Celgene: Business Development and Distributed Research

By: Peter Barrett and Kareem Reda

This case looks at the deal-making process between Celgene, a large publicly traded pharmaceutical company, and Agios, an early-stage biotech company. The framework of a potential deal is explored and the potential road-blocks to Agios’ profitability are discussed. ... View Details

Keywords: Negotiation Deal; Alliances; Collaborative Innovation and Invention; Research; Biotechnology Industry; Biotechnology Industry

June 2014
Supplement

Merrimack Pharmaceuticals, Inc. (B)

By: Amy C. Edmondson, Bethany Gerstein and Melissa Valentine

In 2006, the leadership team at Merrimack Pharmaceuticals, Inc. had to decide whether to keep its R&D organization in functional departments or restructure it into interdisciplinary teams. This case follows the outcomes of this decision from 2006 to mid-2014, and... View Details

Keywords: Organizational Design; Groups and Teams; Collaborative Innovation and Invention; Research and Development; Biotechnology Industry; Biotechnology Industry

April 2010
Teaching Note

The DiagnoFirst Opportunity (TN)

By: Robert C. Pozen

Teaching Note for [309112]. View Details

Keywords: Decisions; Investment; Risk and Uncertainty; Patents; Cash Flow; Venture Capital; Negotiation Deal; Health Care and Treatment; Opportunities; Law; Biotechnology Industry; Biotechnology Industry; United States; Europe

February 2010 (Revised April 2010)
Case

Organization and Strategy at Millennium (A)

By: Julie M. Wulf and Scott Waggoner

This case examines Millennium's strategic and organizational responses to the rapid evolution of the biopharmaceutical industry. In the early 2000s, as Millennium's competitive advantage in early-stage research slipped away and its losses mounted, founder and CEO Mark... View Details

Keywords: Transformation; Leading Change; Management Succession; Organizational Change and Adaptation; Competitive Strategy; Competitive Advantage; Biotechnology Industry; Biotechnology Industry

January 2009
Teaching Note

Biocon: Launching a New Cancer Drug in India (TN)

By: Sunil Gupta and Das Narayandas

Teaching Note for [508026]. View Details

Keywords: Product Launch; Market Timing; Price; Distribution Channels; Marketing Strategy; Health Care and Treatment; Biotechnology Industry; Biotechnology Industry; India

August 2007 (Revised November 2008)
Case

Biocon: Launching a New Cancer Drug in India

By: Sunil Gupta and Das Narayandas

Kiran Majumdar-Shaw, the CEO of Biocon has to make product launch timing, pricing, channel, and communications mix decisions relating to the launch of BioMAb, a new cancer drug in India. View Details

Keywords: Price; Health Care and Treatment; Marketing Strategy; Product Launch; Planning; Biotechnology Industry; Biotechnology Industry; India

March 2006
Teaching Note

Stan Lapidus: Profile of a Medical Entrepreneur (TN)

By: Robert F. Higgins, Richard G. Hamermesh and Erin Seefeld

Teaching Note to (805-087). View Details

Keywords: Personal Development and Career; Entrepreneurship; Business Startups; Biotechnology Industry; Biotechnology Industry

April 2003 (Revised October 2004)
Case

Novartis: The Challenge of Success (B)

By: Sandra J. Sucher and Stacy McManus

When Dr. Daniel Vasella learned of the early Phase 1 trial results, he immediately decided what course of action Novartis would take. Students will be able to examine and assess the concrete steps, and the rationale behind them, that Novartis took in response to this... View Details

Keywords: Decision Making; Moral Sensibility; Innovation and Invention; Distribution; Product Development; Production; Problems and Challenges; Research and Development; Biotechnology Industry; Biotechnology Industry

April 2003 (Revised October 2004)
Case

Novartis: The Challenge of Success (A)

By: Sandra J. Sucher and Stacy McManus

Preliminary results from Phase 1 clinical trials of a newly developed compound, STI571, showed that 31 out of 31 patients with chronic myelogenous leukemia (CML) had their blood counts return to normal. In the world of oncology, this was unheard of. This was the... View Details

Keywords: Decision Making; Health Testing and Trials; Innovation and Invention; Markets; Distribution; Product Development; Production; Problems and Challenges; Research; Research and Development; Complexity; Biotechnology Industry; Biotechnology Industry

2007
Chapter

Fighting AIDS, Fighting Poverty: Customer Centric Marketing in the Generic Antiretroviral Business

By: Rohit Deshpandé and Zoe Chance

Keywords: Health Disorders; Poverty; Product Marketing; Customers; Biotechnology Industry; Biotechnology Industry

2004
Chapter

Genzyme's Gaucher Initiative: Global Risk and Responsibility

By: Christopher A. Bartlett and Andrew N. McLean

Keywords: Health Disorders; Corporate Social Responsibility and Impact; Globalization; Risk and Uncertainty; Biotechnology Industry; Biotechnology Industry

05 Jan 2011
Op-Ed

Funding Unpredictability Around Stem-Cell Research Inflicts Heavy Cost on Scientific Progress

In light of the latest developments of the on-again, off-again, on-again government funding of human embryonic stem-cell research, it is time to consider the devastating implications of this chaotic funding environment. And to do that, one needs to understand how a... View Details

Keywords: by William Sahlman; Biotechnology; Biotechnology; Biotechnology

07 Dec 2015
Research & Ideas

The Rise of Personalized Entrepreneurial Finance and Other VC Trends

flow in terms of what areas are hot or not. Biotechnology was very hot in the 80s and 90s, and then there was a long profound downturn. In the last 18 months it’s becoming really hot again with bioinformatics, which combines information... View Details

Keywords: Re: Josh Lerner; Financial Services; Banking

12 Mar 2013
First Look

First Look: March 12

A. Arnaout Publication:Nature Biotechnology Abstract Advances in biotechnology have fueled the generation of unprecedented quantities of data across the life sciences. However, finding analysts who can... View Details

Keywords: Sean Silverthorne

05 Dec 2013
Op-Ed

Encourage Breakthrough Health Care by Competing on Products Rather Than Patents

Like many people interested in the tangled connections between health care progress and intellectual property rights, I avidly followed the Myriad Genetics case, decided by the Supreme Court this June 13. In sum, molecular diagnostics maker Myriad sought "the... View Details

Keywords: by Richard G. Hamermesh; Biotechnology; Biotechnology

26 Jul 2024
Research & Ideas

Why Great Ideas Get Stuck in Universities

Entrepreneurs must overcome many barriers to get discoveries to market, but academic researchers face an additional one they might not realize: themselves. Academics tend to develop a myopic focus on the unique expertise they spend their lives developing, but that... View Details

Keywords: by Ben Rand; Biotechnology; Biotechnology

May 1999
Teaching Note

Elliot Lebowitz TN

By: Paul A. Gompers

Teaching Note for (9-297-094). View Details

Keywords: Biotechnology Industry

January 1998 (Revised September 2001)
Case

Genset: 1989

By: Paul A. Gompers and Amy Burroughs

Discusses the start-up strategy at Genset, a French biotech firm. Pascal Brandys, a venture capitalist, and Marc Vasseur, a leading French scientist, must decide how to proceed. Future real options are central to the strategy. View Details

Keywords: Strategy; Venture Capital; Business Startups; Biotechnology Industry; France

←
12
13
…
22
23
→